Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Update please

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Dec 29, 2021 1:02pm

171 Views

Post# 34268070

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Update please

Forgive my lack of knowledge in this space, but based on this suggestion, I would have expected to hear of several more Grade 4 (I think is what I read previously) events with neutropenia. Since we've only heard of the one, does that mean they were able to avoid disclosing the others somehow? I was thinking with "all comers" and a lack of a controlled target, that we would have heard of additional issues with toxicity, but we haven't. Why would that be?

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec